Bill Text: TX HCR103 | 2025-2026 | 89th Legislature | Introduced

Texas House Concurrent Resolution 103

Introduced

Bill Title: Expressing support for the Texas Health and Human Services Commission's application to the Cell and Gene Therapy Access Model through the Centers for Medicare and Medicaid Services and its Center for Medicare and Medicaid Innovation.

Sponsorship: Partisan Bill (Democrat 1)

Status: (Introduced - Dead) 2025-03-17 - Referred to s/c on Dis Prev & Women's & Children's Health by Speaker [HCR103 Detail]

Download: Texas-2025-HCR103-Introduced.html

	89R16409 BPG-D

	By: Simmons	H.C.R. No. 103



	CONCURRENT RESOLUTION
	WHEREAS, Cell and gene therapies can transform the lives of
	people living with rare and severe diseases that are difficult to
	treat; and
	WHEREAS, A rapidly growing class of one-time treatments, CGT
	can correct underlying causes of such conditions as sickle cell
	disease, alleviating symptoms and halting progression; these
	treatments have the potential to reduce health care spending over
	the long term by addressing the underlying causes of disease,
	reducing the severity, and decreasing health care utilization; and
	WHEREAS, The high upfront cost of these treatments makes it
	difficult for state Medicaid agencies to pay for them; accordingly,
	the CGT Access Model was created to improve health outcomes for
	people with Medicaid by supporting agreements between states and
	manufacturers that will provide for treatments within a framework
	that lowers prices for states and ties payment to outcomes; and
	WHEREAS, A voluntary program under the Center for Medicare
	and Medicaid Innovation of the federal Centers for Medicare and
	Medicaid Services, the CGT Access Model tests whether a CMS-led
	approach to developing and administering outcomes-based agreements
	for cell and gene therapies expands Medicaid beneficiaries' access
	to innovative treatment, improves their health outcomes, and
	reduces health care costs and burdens to state Medicaid programs;
	under the model, CMS and pharmaceutical manufacturers would
	negotiate a set of key terms, including pricing and outcome
	measures, that would form the basis for individual contracts
	between the manufacturer and participating states; participating
	states would receive CMS technical assistance and funding; and
	WHEREAS, The Texas Health and Human Services Commission has
	evaluated the CGT Therapy Access Model and has applied for
	admission in order to test its innovative payment and service
	delivery models to reduce program expenditures while enhancing the
	quality of care; and
	WHEREAS, Cell and gene therapies offer potentially
	life-changing benefits, and their use for Texas Medicaid patients
	with rare and severe diseases holds the possibility of improving
	health outcomes while lowering long-term costs to the state; now,
	therefore, be it
	RESOLVED, That the 89th Legislature of the State of Texas
	hereby express support for the Texas Health and Human Services
	Commission's application to the Cell and Gene Therapy Access Model
	through the Centers for Medicare and Medicaid Services and its
	Center for Medicare and Medicaid Innovation.